Immune Checkpoint Inhibitors in BCC and CSCC: Aligning Clinical Practice with Best Practices and Guidelines (Virtual)

Description

Here is the Meeting Flyer. 

The Maryland Dermatologic Society cordially invites you to attend a CME activity that aims to improve learners’ knowledge, confidence, and competence in effectively using immune checkpoint inhibitors to improve outcomes in patients with basal cell carcinoma and cutaneous squamous cell carcinoma.

Unfortunately Justine V. Cohen, D.O., had a conflict and cannot make the meeting.

David M. Miller, MD, PhD – Harvard University / Mass General will lead the educational instead. Dr. Miller is one of the very few clinicians in the entire country who is board certified in Internal Medicine, Dermatology and Medical Oncology. He currently practices both Dermatology and Medical Oncology in the MGH Cancer Center and at Massachusetts Eye and Ear Infirmary, where he co-directs multidisciplinary clinics in advanced skin cancer.

AMA PRA Category 1 Credit™, ABIM MOC, ANCC, AAPA, and ACPE- certified live webinar titled, “Immune Checkpoint Inhibitors in BCC and CSCC: Aligning Clinical Practice With Best Practices and Guidelines.”

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Disclosures will be made known to learners before the activity. We invite you to share this event with your colleagues by forwarding this email.

REGISTER

For full accreditation information, click here.